Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

The mRNA technology behind Moderna's Covid vaccine reaches the flu

6 August 2026 · By · Wire by Fusion42

Published

6 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at theguardian.com →

◆ Verified

Fusion42 · 6 August 2026 · Fusion42 review

The FDA has approved Moderna's mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older, marking the first use of mRNA technology for influenza. The vaccine offers faster manufacturing and showed improved immune response and safety in clinical trials compared to existing flu vaccines.

This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 6 Aug 2026 and 7 Aug 2026.

◆ ◆ The Wire takeaway

Older adult vaccine developers must now factor in the mRNA flu vaccine as a new competitor with faster update cycles and potentially better efficacy. You need to evaluate your product's positioning and development pace against Moderna’s mRNA flu vaccine technology.

◆ Coverage

9 sources · first reported 6 Aug 2026 · latest 7 Aug 2026

◆ Topics

BiotechmRNAflu-vaccineFDA-approvalModernavaccine-technology